DK3659627T3 - Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder - Google Patents

Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3659627T3
DK3659627T3 DK19208959.7T DK19208959T DK3659627T3 DK 3659627 T3 DK3659627 T3 DK 3659627T3 DK 19208959 T DK19208959 T DK 19208959T DK 3659627 T3 DK3659627 T3 DK 3659627T3
Authority
DK
Denmark
Prior art keywords
polyphosphate
methods
inorganic nanoparticles
hemostatic compositions
functionalized inorganic
Prior art date
Application number
DK19208959.7T
Other languages
English (en)
Inventor
Damien Kudela
Galen D Stucky
Anna May-Masnou
Gary Bernard Braun
James H Morrissey
Stephanie A Smith
Original Assignee
Univ California
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Univ Illinois filed Critical Univ California
Application granted granted Critical
Publication of DK3659627T3 publication Critical patent/DK3659627T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19208959.7T 2013-03-08 2014-03-07 Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder DK3659627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775354P 2013-03-08 2013-03-08
EP14759780.1A EP2964329B1 (en) 2013-03-08 2014-03-07 Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

Publications (1)

Publication Number Publication Date
DK3659627T3 true DK3659627T3 (da) 2024-04-02

Family

ID=51488074

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14759780.1T DK2964329T3 (da) 2013-03-08 2014-03-07 Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder
DK19208959.7T DK3659627T3 (da) 2013-03-08 2014-03-07 Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14759780.1T DK2964329T3 (da) 2013-03-08 2014-03-07 Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder

Country Status (6)

Country Link
US (6) US9186417B2 (da)
EP (3) EP2964329B1 (da)
DK (2) DK2964329T3 (da)
ES (2) ES2773275T3 (da)
FI (1) FI3659627T3 (da)
WO (1) WO2014138662A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2964329T3 (da) * 2013-03-08 2020-03-16 Univ California Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder
EP3532026B1 (en) 2016-10-27 2022-07-13 El Sabahy, Mahmoud, Fahmy Ali Nanotechnology-based hemostatic dressings
KR102022614B1 (ko) * 2017-02-06 2019-09-18 한양대학교 에리카산학협력단 동적핵분극 기술 기반의 자기공명영상 다공성 실리콘 나노조영제 및 이의 제조방법
US10953130B2 (en) 2017-08-31 2021-03-23 Victor Matthew Phillips Solid hemostatic composition and methods of making the same
CN107998442B (zh) * 2017-12-08 2019-11-26 大连理工大学 外用纳米二氧化硅/聚多巴胺黏附型止血材料及其制备方法
EP4101455A4 (en) * 2020-01-08 2024-02-07 Kamui Pharma, Inc. PLATE AGGREGator
CN111450306B (zh) * 2020-03-06 2021-11-19 大连理工大学 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法
CN117567790B (zh) * 2024-01-15 2024-03-26 四川大学 内部促凝血外表面抗凝血的医用聚氨酯泡沫及其制备方法
WO2025265036A1 (en) * 2024-06-21 2025-12-26 Cayuga Biotech, Inc. Polyphosphate-functionalized nanoparticles and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890648B2 (en) * 2000-02-03 2005-05-10 Nisshin Steel Co., Ltd. CR-free paint compositions and painted metal sheets
KR100338491B1 (ko) * 2000-03-30 2002-05-30 채수경 인중합체로 된 흉터 억제 및 상처 회복 촉진제
BRPI0519739A2 (pt) 2004-12-30 2009-03-10 Cinv Ag combinaÇço compreendendo um agente fornecendo um sinal, um material de implante e uma droga
US8257740B1 (en) * 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2006096345A2 (en) 2005-03-04 2006-09-14 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CN101663581A (zh) * 2007-04-19 2010-03-03 3M创新有限公司 水分散性二氧化硅纳米颗粒在连接生物分子方面的用途
WO2009032994A2 (en) * 2007-09-06 2009-03-12 Emory University Silica-based nanoparticles and methods of stimulating bone formation and suppressing bone resorption through modulation of nf-kb
EP2207537B1 (en) * 2007-10-02 2017-06-14 Fremont Group Ltd Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alpha-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
WO2009046194A2 (en) 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US7927629B2 (en) 2007-10-27 2011-04-19 The Trustees Of The University Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
US8025723B2 (en) * 2008-03-07 2011-09-27 Xerox Corporation Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments
US9241696B2 (en) * 2008-10-30 2016-01-26 Abbott Vascular Inc. Closure device
US8517979B2 (en) * 2008-12-22 2013-08-27 Abbott Laboratories Carriers for hemostatic tract treatment
GB2470040A (en) * 2009-05-06 2010-11-10 Systagenix Wound Man Ip Co Bv Wound dressing material comprising N-acetyl cysteine
US8642088B2 (en) 2009-09-04 2014-02-04 Wisconsin Alumni Research Foundation Tannin-chitosan composites
TW201129698A (en) * 2009-12-10 2011-09-01 Jgc Corp New cell culture method
JP5989661B2 (ja) * 2010-12-17 2016-09-07 コンパニ・ジェルベ・ダノンＣｏｍｐａｇｎｉｅ Ｇｅｒｖａｉｓ Ｄａｎｏｎｅ 消化器の病的状態の改善に使用するためのラクトコッカスラクティス株
EP2489346A1 (en) * 2011-01-26 2012-08-22 NanotecMARIN GmbH Food supplement and injectable material for prophylaxis and therapy of osteoporosis and other bone diseases
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
US20120282320A1 (en) * 2011-05-05 2012-11-08 George H. Scherr Trust Hemostatic dressing
US20130084323A1 (en) * 2011-09-29 2013-04-04 Jerome Riebman Fenestrated hemostatic patch
EP3443916A3 (en) 2012-05-15 2019-04-24 Pulse Therapeutics, Inc. Magnetic-based systems
WO2013185032A1 (en) 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
JP6334550B2 (ja) 2012-11-06 2018-05-30 インベッド バイオサイエンシズ，インコーポレイテッド 創傷治癒の方法と組成物
DK2964329T3 (da) * 2013-03-08 2020-03-16 Univ California Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder
DE102013222223A1 (de) 2013-10-31 2015-04-30 Bk Giulini Gmbh Blutstillendes Mittel enthaltend kristallines Polyphosphat

Also Published As

Publication number Publication date
US20200023096A1 (en) 2020-01-23
EP2964329B1 (en) 2019-12-25
EP4360656A2 (en) 2024-05-01
US20260000809A1 (en) 2026-01-01
US20210213159A1 (en) 2021-07-15
FI3659627T3 (fi) 2024-03-27
US20140255336A1 (en) 2014-09-11
WO2014138662A1 (en) 2014-09-12
US11707550B2 (en) 2023-07-25
US9186417B2 (en) 2015-11-17
US20240157022A1 (en) 2024-05-16
EP2964329A1 (en) 2016-01-13
ES2773275T3 (es) 2020-07-10
US20160213809A1 (en) 2016-07-28
US10842908B2 (en) 2020-11-24
ES2970986T3 (es) 2024-06-03
EP4360656A3 (en) 2024-07-24
EP3659627B1 (en) 2024-02-14
US12350399B2 (en) 2025-07-08
US10293077B2 (en) 2019-05-21
EP3659627A1 (en) 2020-06-03
DK2964329T3 (da) 2020-03-16
EP2964329A4 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
IL274064A (en) Compositions and methods for modulating apolipoprotein (a) expression
IL241112B (en) Methods and compositions for modification of hla
HRP20180817T1 (hr) Sastavi i postupci za modulaciju farnesoid-x-receptora
BR112015028459A2 (pt) composições e comestíveis
EP2991946A4 (en) Pumice-containing remedial compositions and methods of use
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
EP2953474A4 (en) COMPOSITIONS AND METHODS
PL4000608T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
HUE053410T2 (hu) Alkalmazási eljárás és alkalmazási berendezés
BR112015023679A2 (pt) composições e métodos para imunoterapia
SG11201507867RA (en) Antimicrobial compositions and methods of use
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK2964329T3 (da) Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
PL3007695T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
IL244259B (en) Delivery of medical devices
EP3039131C0 (en) ENZYME COMPOSITION AND USES
EP2970569A4 (en) PERSISTENT CARBENE AND COMPOSITIONS WITH IT
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
DK3060200T3 (da) Tyrosinderivater og sammensætninger dermed
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
HUE043417T2 (hu) Krémesítõ kompozíciók és alkalmazásuk
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
SG11201506869YA (en) Antimicrobial compositions and related methods of use